Drinking water in Europe...that's massive!
"Treatment of European Drinking Water Reservoir Posted on April 17th, 2019 by Sarah Groves
A large-scale potable water supply reservoir in Western Europe was treated with Phoslock during March. The treatment was the first stage in a two stage project, with a second application planned for June 2019. The total value of the project is more than A$400,000.The project is a milestone project for Phoslock Environmental Technologies (PET) as the reservoir is located in one of Europe’s most densely populated countries and it was not possible to take the reservoir offline during the treatment. Consequently, water continued to be abstracted for the duration of the treatment.The reservoir is located in an area of intensive agriculture, with the result that phosphorus levels in the water feeding the reservoir and the plant are very high. In recent years, this has triggered algal blooms and caused operational issues for the plant. The aim of the application is to reduce phosphorus and algal concentrations in the water abstracted from the reservoir into the treatment plant, so that treatment costs can be lowered.The use of Phoslock in potable water supply reservoirs in other countries such as Brazil have resulted in significant reductions in blue green algal concentrations and led to reduced operational costs in the treatment plants.The results of the application will be monitored closely by PET and the water company which operates the plant/reservoir. Further applications are likely in other locations over the next 12 months."
- Forums
- ASX - By Stock
- PET
- europe
europe, page-4
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PET (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.60M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
PET (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online